AKT1 and neoplasm: Specific effects of NVP-BEZ235 on the PI3K/Akt pathway in vivo were confirmed by immunohistochemistry on tumor tissues at the end of treatments by using immunohistochemical evaluation of p-S6RPser240/244 in controls or in tumors derived from mice treated with the different regimens.